Decoding the Role of CD271 in Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 4

PMID 32878000

Citations 16

Authors

Anna Vidal

Torben Redmer

Affiliations

Soon will be listed here.

Abstract

The evolution of melanoma, the most aggressive type of skin cancer, is triggered by driver mutations that are acquired in the coding regions of particularly BRAF (rat fibrosarcoma serine/threonine kinase, isoform B) or NRAS (neuroblastoma-type ras sarcoma virus) in melanocytes. Although driver mutations strongly determine tumor progression, additional factors are likely required and prerequisite for melanoma formation. Melanocytes are formed during vertebrate development in a well-controlled differentiation process of multipotent neural crest stem cells (NCSCs). However, mechanisms determining the properties of melanocytes and melanoma cells are still not well understood. The nerve growth factor receptor CD271 is likewise expressed in melanocytes, melanoma cells and NCSCs and programs the maintenance of a stem-like and migratory phenotype via a comprehensive network of associated genes. Moreover, CD271 regulates phenotype switching, a process that enables the rapid and reversible conversion of proliferative into invasive or non-stem-like states into stem-like states by yet largely unknown mechanisms. Here, we summarize current findings about CD271-associated mechanisms in melanoma cells and illustrate the role of CD271 for melanoma cell migration and metastasis, phenotype-switching, resistance to therapeutic interventions, and the maintenance of an NCSC-like state.

Citing Articles

The roles of cancer stem cells and therapeutic implications in melanoma.

Mu X, Zhou Y, Yu Y, Zhang M, Liu J Front Immunol. 2024; 15:1486680.

PMID: 39611156 PMC: 11602477. DOI: 10.3389/fimmu.2024.1486680.

Leveraging Neural Crest-Derived Tumors to Identify NF1 Cancer Stem Cell Signatures.

Khan S, Alson D, Sun L, Maloney C, Sun D Cancers (Basel). 2024; 16(21).

PMID: 39518076 PMC: 11545784. DOI: 10.3390/cancers16213639.

Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies.

Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).

PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

Pharmacological agents targeting drug-tolerant persister cells in cancer.

Chen Y, Gowda K, Amin S, Schell T, Sharma A, Robertson G Pharmacol Res. 2024; 203():107163.

PMID: 38569982 PMC: 11734664. DOI: 10.1016/j.phrs.2024.107163.

References

Rankin E, Giaccia A . Hypoxic control of metastasis. Science. 2016; 352(6282):175-80. PMC: 4898055. DOI: 10.1126/science.aaf4405. View

Quintana E, Shackleton M, Foster H, Fullen D, Sabel M, Johnson T . Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010; 18(5):510-23. PMC: 3031091. DOI: 10.1016/j.ccr.2010.10.012. View

Tomellini E, Lagadec C, Polakowska R, Le Bourhis X . Role of p75 neurotrophin receptor in stem cell biology: more than just a marker. Cell Mol Life Sci. 2014; 71(13):2467-81. PMC: 11113797. DOI: 10.1007/s00018-014-1564-9. View

Restivo G, Diener J, Cheng P, Kiowski G, Bonalli M, Biedermann T . Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nat Commun. 2018; 9(1):314. PMC: 5778081. DOI: 10.1038/s41467-018-02850-8. View

Mochizuki M, Tamai K, Imai T, Sugawara S, Ogama N, Nakamura M . CD271 regulates the proliferation and motility of hypopharyngeal cancer cells. Sci Rep. 2016; 6:30707. PMC: 4965829. DOI: 10.1038/srep30707. View

Wen S, Liu Y, Yang M, Yang K, Huang J, Feng D . Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. Oncol Rep. 2016; 36(4):2193-9. DOI: 10.3892/or.2016.5009. View

Hartman M, Czyz M . MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2014; 72(7):1249-60. PMC: 4363485. DOI: 10.1007/s00018-014-1791-0. View

Bilderback T, Grigsby R, Dobrowsky R . Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J Biol Chem. 1997; 272(16):10922-7. DOI: 10.1074/jbc.272.16.10922. View

Redmer T . Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Mol Cancer. 2018; 17(1):106. PMC: 6064184. DOI: 10.1186/s12943-018-0854-5. View

10.

Nykjaer A, Willnow T . Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012; 35(4):261-70. DOI: 10.1016/j.tins.2012.01.003. View

11.

Schachtrup C, Ryu J, Mammadzada K, Khan A, Carlton P, Perez A . Nuclear pore complex remodeling by p75(NTR) cleavage controls TGF-β signaling and astrocyte functions. Nat Neurosci. 2015; 18(8):1077-80. PMC: 4878404. DOI: 10.1038/nn.4054. View

12.

Filipp F, Li C, Boiko A . CD271 is a molecular switch with divergent roles in melanoma and melanocyte development. Sci Rep. 2019; 9(1):7696. PMC: 6531451. DOI: 10.1038/s41598-019-42773-y. View

13.

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

14.

Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R . Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Lett. 2015; 361(1):86-96. DOI: 10.1016/j.canlet.2015.02.041. View

15.

Morrison S, White P, Zock C, Anderson D . Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell. 1999; 96(5):737-49. DOI: 10.1016/s0092-8674(00)80583-8. View

16.

Obenauf A, Massague J . Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 2017; 1(1):76-91. PMC: 4673677. DOI: 10.1016/j.trecan.2015.07.009. View

17.

Ahn B, Saldanha-Gama R, Rahn J, Hao X, Zhang J, Dang N . Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1. Oncogene. 2015; 35(11):1411-22. PMC: 4800290. DOI: 10.1038/onc.2015.199. View

18.

Mundell N, Labosky P . Neural crest stem cell multipotency requires Foxd3 to maintain neural potential and repress mesenchymal fates. Development. 2011; 138(4):641-52. PMC: 3026411. DOI: 10.1242/dev.054718. View

19.

Le Douarin N, Dupin E . Multipotentiality of the neural crest. Curr Opin Genet Dev. 2003; 13(5):529-36. DOI: 10.1016/j.gde.2003.08.002. View

20.

Yaar M, Grossman K, Eller M, Gilchrest B . Evidence for nerve growth factor-mediated paracrine effects in human epidermis. J Cell Biol. 1991; 115(3):821-8. PMC: 2289176. DOI: 10.1083/jcb.115.3.821. View